Trofinetide's Rett syndrome benefit is modest and diarrhea is common

What is trofinetide?

Trofinetide is a synthetic version of glycine-proline-glutamate (GPE), the naturally occurring tripeptide cleaved from the front end of the IGF-1 molecule, with a methyl group added to improve its pharmacokinetic behavior ^[6]⁠^[4]. The modification matters because unmodified GPE has a short half-life and does not hold up well as a drug candidate on its own ^[5].

The FDA approved trofinetide on March 10, 2023, for Rett syndrome in patients aged 2 and up ^[6]⁠^[3]. Rett syndrome is a rare X-linked neurodevelopmental disorder driven by MECP2 mutations that occurs almost exclusively in females ^[6]⁠^[3].

Does trofinetide work like IGF-1?

No. Trofinetide's proposed mechanism does not run through the classic IGF-1 receptor, and trofinetide does not drive growth or anabolic effects ^[8]. Trofinetide is not IGF-1 or a fragment sold to mimic IGF-1's growth signaling.

Preclinical work indicates that GPE and its analogs do not interact with IGF-1 receptors the way IGF-1 does, and points instead to effects on post-injury inflammation, astrogliosis, and vascular remodeling ^[8]. The working hypothesis in Rett syndrome centers on glial and synaptic modulation, and the field describes the mechanism as not yet fully established ^[6].

Reasoning from "contains IGF-1's tripeptide" to "acts like IGF-1" is a jump the pharmacology does not support. The IGF-1 LR3 evidence review covers an analog built for growth signaling.

How was trofinetide tested in Rett syndrome?

Trofinetide's core evidence is LAVENDER, one randomized, double-blind, placebo-controlled Phase 3 trial in 187 females aged 5-20 with Rett syndrome, treated for 12 weeks ^[4]. Its co-primary endpoints were the Rett Syndrome Behaviour Questionnaire (RSBQ, caregiver-rated) and the Clinical Global Impression-Improvement scale (CGI-I, clinician-rated) ^[4].

An earlier Phase 2 trial in 82 patients showed improvement over placebo at the highest tested dose, 200 mg/kg twice daily, on three measures at p ≤ 0.042 ^[4]. That result is statistically significant but not a large margin.

How large is trofinetide's benefit in Rett syndrome?

Trofinetide's benefit is modest: on the key secondary communication endpoint, trofinetide beat placebo by 1.0 point on a 0-26 scale, a Cohen's d of 0.43 ^[2]. That endpoint was the caregiver-rated CSBS-DP-IT Social Composite score (least-squares mean difference 1.0, 95% CI 0.3 to 1.7, p = 0.0064) ^[2]. A clinician-rated nonverbal communication scale showed a difference of -0.3 points that reached only nominal significance (p = 0.0257, d = 0.36) ^[2].

These are real, randomized-trial-grade differences, not noise, but they are small in absolute terms and rest largely on subjective caregiver and clinician ratings, not objective physiological measures.

What do the LILAC and DAFFODIL studies show?

Every trofinetide study after LAVENDER, including LILAC and DAFFODIL, is open-label and uncontrolled, which limits what it can prove. None of the post-approval work is a second randomized trial.

LILAC was a 40-week extension with 154 participants and long-term safety as its primary endpoint ^[1]. Its RSBQ and CGI-I figures compare the two original LAVENDER arms after both had switched to open-label trofinetide, so the roughly equivalent week-40 scores (RSBQ change -7.3 vs -7.0; CGI-I 3.1 vs 3.2) read only as descriptive follow-up, not as drug-versus-placebo separation ^[1].

DAFFODIL enrolled 15 children aged 2-4 years. It confirmed that weight-based dosing hit target drug exposure and described exploratory improvements on CGI measures, but it was also open-label and small ^[3].

How common is diarrhea on trofinetide?

Diarrhea is trofinetide's defining side effect, occurring in 74.7% of participants in the 40-week LILAC extension ^[1]. Vomiting occurred in 28.6%, and diarrhea was the leading cause of treatment discontinuation, affecting 21.4% of the cohort ^[1]. In DAFFODIL's younger cohort, diarrhea occurred in 80.0% and vomiting in 53.3%, described as mild to moderate ^[3].

Rett syndrome itself confounds part of this burden: over 90% of people with the condition have baseline gastrointestinal comorbidities independent of any drug. That background complicates attributing every GI event to trofinetide and argues for proactive GI management alongside treatment ^[7].

How many patients stay on trofinetide in real-world use?

In claims data on 1,175 patients who started trofinetide, 54.9% remained persistent on therapy and 45.1% did not ^[9]. Persistent patients stayed on treatment a median of 14.3 months versus 3.0 months for those who discontinued, and more than three-quarters of initiators remained on treatment past three months ^[9]. The 45.1% who stopped are a meaningful minority, walking away largely for GI reasons.

How is trofinetide dosed?

Trofinetide is a twice-daily oral liquid dosed by body weight, not a fixed amount, and DAFFODIL validated that this weight-based approach achieves the intended drug exposure in children as young as 2 ^[3]. Background on oral peptide delivery is in why peptides can't be swallowed, and the guide to recording a prescribed plan and its outcomes covers tracking a regimen.

Does GPE sold on its own carry trofinetide's evidence?

The GPE or glypromate peptide marketed on its own carries none of trofinetide's evidence. Unmodified GPE is a different molecule with acknowledged pharmacokinetic limitations, and it never completed the trial program trofinetide did ^[5]⁠^[8]. Sharing three letters of a chemical name is not the same as sharing a clinical trial.

What is still unknown about trofinetide?

Trofinetide's open questions are other uses, long-term safety, who stops, and mechanism.

• Uses beyond Rett syndrome. None of the trials cited below supports any other use of trofinetide, cognitive, anabolic, or otherwise.
• Safety past 40 weeks. Safety data beyond roughly 40 weeks of continuous use are limited to the extension study population.
• Who stops treatment. Predictors of who discontinues trofinetide in real-world use are only partially characterized ^[9].
• Mechanism. How trofinetide acts in Rett syndrome is not yet fully established ^[6].